1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsFunctional Target Validation for Alzheimer's Disease-Related Dementias is sponsored by National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS). This opportunity supports mission-aligned projects and measurable outcomes.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Opportunity Listing - Functional Target Validation for Alzheimer's Disease-Related Dementias Functional Target Validation for Alzheimer's Disease-Related Dementias Agency: National Institutes of Health Assistance Listings: 93. 853 -- Extramural Research Programs in the Neurosciences and Neurological Disorders Last Updated: May 13, 2026 View version history on Grants.
gov The National Institute of Neurological Disorders and Stroke (NINDS) is interested in supporting ambitious research projects that propose comprehensive functional validation of newly identified therapeutic target candidates for Alzheimer’s Disease–Related Dementias (ADRD).
A major barrier to the development of effective treatments for ADRD, as well as other complex central nervous system disorders, is the lack of well-validated targets that are clearly linked to disease mechanisms.
Successful translation of basic discoveries into the clinic depends on the rigor of target validation and confidence in a causal relationship between modulation of a target and its functional physiological consequences relevant to treating or preventing disease. This initiative aims to de-risk subsequent translational research and accelerate the development of novel therapeutic strategies.
NINDS believes that this initiative would be most appropriately supported by a phased award mechanism (for example, R61/R33). In the initial phase, support would be provided for the development of customized technologies, models, and protocols to modulate the expression or activity of candidate targets and to assess their physiological consequences in relevant in vitro and in vivo disease models.
Upon successful achievement of predefined, milestone-based technical feasibility and proof-of-concept criteria, projects would transition to the second phase focused on measuring and cross-validating the effects of target modulation across multiple experimental modalities and collaborating laboratories, in accordance with NIH rigor and reproducibility guidelines. Applications are not being solicited at this time.
Notice is being provided to allow potential applicants sufficient time to develop responsive projects and establish appropriate cross-disciplinary collaborations.
Other Native American tribal organizations Nonprofits non-higher education without 501(c)(3) Nonprofits non-higher education with 501(c)(3) City or township governments Federally recognized Native American tribal governments Public and Indian housing authorities Special district governments Independent school districts Public and state institutions of higher education Private institutions of higher education For-profit organizations other than small businesses Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions) are not allowed Grantor contact information Please contact via e-mail NINDSDTRADRD@mail.
nih. gov NINDSDTRADRD@mail. nih.
gov No documents are currently available. Link to additional information Estimated Application Due Date : Estimated Due Date Description : Estimated Project Start Date : Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity : Your account requires additional identity verification.
According to the current listing, eligibility includes: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Non-domestic (non-U. Confirm the full requirements in the official notice before applying.
The current listing shows $1,800,000 (Award Ceiling). Verify award ceilings, matching requirements, and allowable costs in the official notice.
Functional Target Validation for Alzheimer's Disease-Related Dementias is funded by National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS). Verify program details on the funder's official page before applying.
This opportunity targets applicants in Alaska. If your organization operates elsewhere, check the official notice for location requirements.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
NINDS Exploratory Grant Program in Parkinson's Disease Research (P20- Clinical Trial Optional) is sponsored by National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS). This funding opportunity supports exploratory research in Parkinson's disease. The P20 mechanism encourages innovative, high-risk/high-reward research that may lay the groundwork for future larger-scale studies.
HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional) is sponsored by National Institutes of Health (NIH), National Institute of Neurological Disorders and Stroke (NINDS). This funding opportunity, part of the NIH HEAL Initiative, supports the development of non-addictive therapeutics for pain. While not exclusively critical care, pain management is a significant aspect of critical care, making this relevant for universities conducting related research.
PAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read articleThe HEAL Initiative's Studies to Enable Analgesic Discovery award (RFA-NS-25-023) puts federal money exactly where private capital won't go — the assay-building, screening, and hit-characterization stage of non-opioid pain therapeutics. It's a phased R61/R33, up to $350,000 in direct costs per year, with the next application deadline September 17, 2026. Here is how the two-phase structure works, who's eligible, and how to build a proposal that survives the R61-to-R33 milestone gate.
Read articlePA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read article